Lv4
420 积分 2024-11-15 加入
The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer
2天前
已完结
Monitoring minimal residual disease using circulating tumor DNA in patients treated long-term with PARP inhibitors for ovarian cancer
2天前
已关闭
Phase II investigation of pembrolizumab in combination with bevacizumab and oral cyclophosphamide in patients with high grade ovarian cancer and surgical or molecular minimal residual disease after frontline therapy
2天前
已关闭
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
11天前
已完结
ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
18天前
已完结
The pancreatic cancer drug market
22天前
已完结
Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skipping or de novo MET amplification
27天前
已完结
The prevalence of HLA‐I LOH in Chinese pan‐cancer patients and genomic features of patients harboring HLA‐I LOH
30天前
已完结
ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial
1个月前
已完结
Field-effect-informed urine liquid biopsy for bladder cancer
1个月前
已完结
皖公网安备34019202002308
